Top

International Journal of Colorectal Disease

Published in:

01-10-2015 | Original Article

Complications from the primary tumour are not related with survival in patients with synchronous stage IV colorectal cancer receiving chemotherapy without primary tumour resection

Authors: Javier Suárez, Gabriel Marín, Ruth Vera, Begoña Oronoz, Fabiola Oteiza, Elena Mata

Published in: International Journal of Colorectal Disease | Issue 10/2015

Abstract

Background

The aim of this study was to evaluate the rate of complications from the primary tumour (CPT) requiring surgical or endoscopic intervention during chemotherapy treatment in patients with incurable synchronous stage IV colorectal cancer, the possibility of predicting such complications and their influence on survival.

Methods

One hundred and twenty-five patients were initially treated with chemotherapy. Patients were grouped on the basis of appearance or not of CPT. We assessed the relation between age, gender, carcinoembryonic antigen (CEA) level, primary tumour location, alkaline phosphatase level, unilobar or bilobar liver involvement, presence of peritoneal carcinomatosis, the number of sites of metastatic disease, the addition of target therapies to chemotherapy, the ability to traverse the tumour with an endoscope and the appearance of complications due to the primary tumour and overall survival.

Results

Mean age was 64.9 years, and 89 patients were men. Over a mean of 234 days, 25 patients (20 %) developed a CPT. Eighteen patients required surgery, and seven were treated exclusively by an endoscopic procedure. Mean survival was 15.8 months. We found a statistically relevant correlation between the inability to traverse the tumour with an endoscope and the occurrence of a CPT. There was no statistical differences in survival between both groups, but patients receiving target therapies had better survival.

Conclusion

Twenty percent of patients will suffer a CPT during chemotherapy treatment. The inability to pass the tumour with an endoscope can predict the CPT. Survival was only related to the addition of target therapies to chemotherapy.

Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ (1997) Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 84(12):1731–6CrossRefPubMed

Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Tenière P, Paillot B (2004) Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol 28(5):434–7CrossRefPubMed

Mahteme H, Påhlman L, Glimelius B, Graf W (1996) Prognosis after surgery in patients with incurable rectal cancer: a population-based study. Br J Surg 83(8):1116–20CrossRefPubMed

Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24(4):668–74CrossRefPubMed

Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19(11):1829–35CrossRefPubMed

Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27(20):3379–84PubMedCentralCrossRefPubMed

Stelzner S, Hellmich G, Koch R, Ludwig K (2005) Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 89(4):211–7CrossRefPubMed

Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingston S, Andreyev J (2003) Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52(4):568–73PubMedCentralCrossRefPubMed

Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196(5):722–8CrossRefPubMed

10.

Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G, Platell C (2012) Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 8:CD008997. doi:10.1002/14651858.CD008997 PubMed

11.

Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19(11):1829–35. doi:10.1093/annonc/mdn398 CrossRefPubMed

12.

Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Mol L, Punt CJ, Koopman M (2011) Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 18(12):3252–60. doi:10.1245/s10434-011-1951-5 PubMedCentralCrossRefPubMed

13.

Dutch Colorectal Cancer Group. The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colon cancer (CAIRO4). NCT01606098.

14.

Yonsei University. A randomized, prospective, multicenter study for the role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis. NCT01978249

15.

Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14(2):766–70CrossRefPubMed

16.

McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, Wagman LD, O'Connell MJ, Wolmark N (2012) Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 30(26):3223–8. doi:10.1200/JCO.2012.42.4044 PubMedCentralCrossRefPubMed

17.

Matsumoto T, Hasegawa S, Matsumoto S, Horimatsu T, Okoshi K, Yamada M, Kawada K, Sakai Y (2014) Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor. Dis Colon Rectum 57(6):679–86. doi:10.1097/DCR.0000000000000025 CrossRefPubMed

18.

Miyamoto Y, Watanabe M, Sakamoto Y, Shigaki H, Murata A, Sugihara H, Etoh K, Ishimoto T, Iwatsuki M, Baba Y, Iwagami S, Yoshida N, Baba H (2014) Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer. Surg Today 44(12):2287–92. doi:10.1007/s00595-014-0869-5 CrossRefPubMed

19.

Benoist S, Pautrat K, Mitry E et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160CrossRefPubMed

20.

Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, Ledermann JA, O'Bichere A (2009) Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol 35(2):164–7. doi:10.1016/j.ejso.2008.06.005 CrossRefPubMed

21.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–42CrossRefPubMed

22.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–17. doi:10.1056/NEJMoa0805019 CrossRefPubMed

23.

Law WL, Chan WF, Lee YM, Chu KW (2004) Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis 19(3):197–202CrossRefPubMed

Title: Complications from the primary tumour are not related with survival in patients with synchronous stage IV colorectal cancer receiving chemotherapy without primary tumour resection
Authors: Javier Suárez
Gabriel Marín
Ruth Vera
Begoña Oronoz
Fabiola Oteiza
Elena Mata
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 10/2015
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-015-2305-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Complications from the primary tumour are not related with survival in patients with synchronous stage IV colorectal cancer receiving chemotherapy without primary tumour resection

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2015

Defining characteristics of patients with colorectal cancer requiring emergency surgery

Two different gracilis loops in graciloplasty of congenital fecal incontinence: comparison of the therapeutic effects

Effect of preoperative colonoscopic tattooing on lymph node harvest in T1 colorectal cancer

Severity of inflammation as a risk factor for ileo-anal anastomotic leak after a pouch procedure in ulcerative colitis

Coloduodenal fistula due to signet-ring cells adenocarcinoma

How many segments are necessary to characterize delayed colonic transit time?